Status:
COMPLETED
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Hepatic Cirrhosis
Liver Fibrosis
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
This is a study of experimental medication BMS-986036 given to healthy participants.
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Healthy participant, as determined by no clinically significant deviations from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- BMI of 18 to ≤ 40 kg/m2
Exclusion
- Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds)
- Any bone trauma (fracture) or bone surgery (i.e. hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration
- Known or suspected autoimmune disorder, excluding vitiligo
- Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) gastrointestinal disease
- Any major surgery within 6 weeks of study drug administration
- History of diabetes mellitus
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
February 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 2 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03445208
Start Date
February 14 2018
End Date
May 2 2018
Last Update
March 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences
Salt Lake City, Utah, United States, 84107